论文部分内容阅读
目的:观察利妥昔单抗注射液联合化疗治疗B细胞非霍奇金淋巴瘤(B-NHL)的疗效。方法:将2013年1月至2014年12月我院收治的71例B-NHL患者分为对照组(n=35例)和观察组(n=36例)。对照组给予常规化疗方案进行治疗,观察组在此基础上加用利妥昔单抗进行治疗,3个周期后评价其疗效及安全性。结果:观察组总有效率为91.67%,明显高于对照组的68.57%,对比差异有统计学意义(x2=5.979,P<0.05);观察组不良反应总发生率为41.67%,略低于对照组的45.71%,但无统计学差异(x2=0.118,P>0.05)。结论:利妥昔单抗注射液联合化疗治疗B-NHL中期疗效显著,且无严重不良反应,值得临床推广。
Objective: To observe the efficacy of rituximab injection combined with chemotherapy in the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL). Methods: From January 2013 to December 2014, 71 B-NHL patients admitted to our hospital were divided into control group (n = 35) and observation group (n = 36). The control group was given routine chemotherapy regimen. The observation group was treated with rituximab on the basis of the above treatment. After 3 cycles, the curative effect and safety were evaluated. Results: The total effective rate in the observation group was 91.67%, significantly higher than that in the control group (68.57%), the difference was statistically significant (x2 = 5.979, P <0.05). The overall incidence of adverse reactions in the observation group was 41.67% Control group, 45.71%, but no significant difference (x2 = 0.118, P> 0.05). Conclusion: Rituximab injection combined with chemotherapy in the treatment of B-NHL mid-term significant effect, and no serious adverse reactions, is worth clinical promotion.